AtaiBeckley Inc. (ATAIN)
BMV
Delayed Data
Nov 20, 2025, 02:30 PM
Day's Range
68.0052 wk Range
26.40Overview - ATAIN - AtaiBeckley Inc.
Key Statistics
Valuation
Enterprise Value
431.23B
Price / Book
5.71
EV / EBITDA
-242.42
Profitability
Profit Margin
0.00%
Operating Margin
-3,796.52%
Return on Assets
-29.24%
Return on Equity
-100.77%
Ownership
Float
301.25M
Held by Insiders
3.69%
Held by Institutions
28.18%
Price stats
Beta
1.61
50-Day Avg
77.22
200-Day Avg
77.22
Peers - ATAIN - AtaiBeckley Inc.
Peer Comparison
Compared with companies in Biotechnology listed on BMV.
- ATAINBMVAtaiBeckley Inc.-60.43%52-week change—P/E (Trailing)0.00%Profit Margin
- ARGXNBMVargenx SE American Depositary Receipt+10.77%52-week change35.84P/E (Trailing)32.26%Profit Margin
- ASND1NBMVAscendis Pharma A/S+3.50%52-week change18.84P/E (Trailing)70.84%Profit Margin
- BMRNBMVBioMarin Pharmaceutical Inc.+10.22%52-week change165.92P/E (Trailing)2.14%Profit Margin
- AGIOBMVAgios Pharmaceuticals, Inc.+0.00%52-week change5.73P/E (Trailing)88.25%Profit Margin
- ARWRBMVArrowhead Pharmaceuticals, Inc.+0.00%52-week change-45455.00P/E (Trailing)-47.79%Profit Margin
- BEAMBMVBeam Therapeutics Inc.-9.05%52-week change-559.26P/E (Trailing)-55.44%Profit Margin
Profile Summary - ATAIN - AtaiBeckley Inc.
About
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing mental health treatments. The company concentrates on rapid-acting, durable, and convenient therapies designed to address difficult-to-treat psychiatric conditions, including depression, treatment-resistant depression, social anxiety…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
